Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$51.49 - $81.64 $717,255 - $1.14 Million
-13,930 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$60.03 - $76.49 $836,217 - $1.07 Million
13,930 New
13,930 $1.06 Million
Q3 2020

Nov 16, 2020

SELL
$51.97 - $63.0 $21 Million - $25.5 Million
-405,040 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$30.8 - $52.47 $14.9 Million - $25.3 Million
-482,330 Reduced 54.36%
405,040 $21.3 Million
Q1 2020

May 15, 2020

BUY
$28.4 - $50.7 $3.3 Million - $5.89 Million
116,230 Added 15.07%
887,370 $29.8 Million
Q4 2019

Feb 14, 2020

BUY
$36.31 - $46.83 $28 Million - $36.1 Million
771,140 New
771,140 $34.9 Million
Q2 2019

Aug 14, 2019

SELL
$36.57 - $47.97 $25.8 Million - $33.9 Million
-706,379 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$36.47 - $42.17 $65.3 Million - $75.6 Million
-1,791,749 Reduced 71.72%
706,379 $26.9 Million
Q4 2018

Feb 14, 2019

SELL
$41.31 - $52.16 $14.8 Million - $18.6 Million
-357,085 Reduced 12.51%
2,498,128 $107 Million
Q4 2018

Feb 14, 2019

BUY
$41.31 - $52.16 $37.6 Million - $47.4 Million
909,673 Added 46.76%
2,855,213 $91.5 Million
Q3 2018

Nov 15, 2018

SELL
$32.85 - $52.0 $29.9 Million - $47.3 Million
-909,673 Reduced 31.86%
1,945,540 $95.6 Million
Q2 2018

Aug 14, 2018

BUY
$27.5 - $39.8 $15.3 Million - $22.1 Million
555,213 Added 24.14%
2,855,213 $91.5 Million
Q1 2018

May 15, 2018

SELL
$29.98 - $46.35 $15 Million - $23.2 Million
-500,000 Reduced 17.86%
2,300,000 $71.6 Million
Q4 2017

Feb 14, 2018

BUY
$31.85 - $46.95 $7.07 Million - $10.4 Million
221,960 Added 8.61%
2,800,000 $128 Million
Q3 2017

Nov 14, 2017

BUY
$35.7 - $39.5 $92 Million - $102 Million
2,578,040
2,578,040 $96.8 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.31B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Health Cor Management, L.P. Portfolio

Follow Health Cor Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Health Cor Management, L.P. with notifications on news.